Abstract: The present technology relates to a polymer comprising at least one ester repeating unit and one ether repeating unit for use in an electrochemical cell, particularly in electrochemical accumulators such as lithium batteries, sodium batteries, potassium batteries and lithium-ion batteries. More specifically, the use of this polymer as a solid polymer electrolyte (SPE), as a matrix for forming gel electrolytes, or as a binder in an electrode material are also contemplated.

Abstract: All-solid-state electrochemical cells comprising an inorganic particle-polymer composite, where the polymer is a crosslinked polymer and the content of inorganic particles in the composite is at least 50 wt. % are described. Also described are processes for the preparation of such all-solid-state electrochemical cells, all-solid-state batteries comprising them and their uses in mobile devices, electric or hybrid vehicles, or in renewable energy storage.

Abstract: The present technology relates to inorganic compounds having an argyrodite-type structure based on an alkali metal obtained by a preparation process comprising a step of grinding the sulfide of the alkali metal, the sulfate of the alkali metal, phosphorus pentasulfide and a halide of the alkali metal. Also described are electrode materials, electrodes, electrolytes comprising said inorganic compound having an argyrodite-type structure and their uses in electrochemical cells, for example, in electrochemical accumulators, particularly in all-solid-state batteries.

Abstract: Here are described processes for the preparation of sulfamic acid derivatives, for instance, halogenated derivatives and their metallic or organic salts. The present document also describes the sulfamic acid derivatives thus produced and to their uses, for instance, in electrolyte compositions for electrochemical applications.

Abstract: A protective material for protecting a lithium metal sheet, in particular a lithium metal anode. The material comprises a metal fluoride such as AlF3 and a fluoro alkylene carbonate such as fluoro ethylene carbonate (FEC). A method for using the protective material is provided.

Abstract: The present technology relates to a polymer comprising at least one ester repeating unit and one ether repeating unit for use in an electrochemical cell, particularly in electrochemical accumulators such as lithium batteries, sodium batteries, potassium batteries and lithium-ion batteries. More specifically, the use of this polymer as a solid polymer electrolyte (SPE), as a matrix for forming gel electrolytes, or as a binder in an electrode material are also contemplated.

Abstract: Here are described processes for the preparation of sulfamic acid derivatives, for instance, halogenated derivatives and their metallic or organic salts. The present document also describes the sulfamic acid derivatives thus produced and to their uses, for instance, in electrolyte compositions for electrochemical applications.

Abstract: All-solid-state lithium-sulfur electrochemical cells and production methods thereof are described. The Li—S electrochemical cells comprise at least one multilayer component which comprises an ion-conductive solid electrolyte film, a positive electrode film containing a sulfur composite, and a negative electrode film containing lithium. Positive electrodes films, prefabricated electrolyte-positive electrode elements, their uses as well as methods of their production are also described.

Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic selected from the group consisting of neurotensin, a neurotensin analog, or a neurotensin receptor agonist. The compounds of the invention can be used to treat any disease in which increased neurotensin activity is useful and can be used to induce hypothermia or analgesia.

Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic. The compounds of the invention can be used to treat any disease for which the peptide therapeutic is useful.

Abstract: All-solid-state lithium-sulfur electrochemical cells and production methods thereof are described. The Li—S electrochemical cells comprise at least one multilayer component which comprises an ion-conductive solid electrolyte film, a positive electrode film containing a sulfur composite, and a negative electrode film containing lithium. Positive electrodes films, prefabricated electrolyte-positive electrode elements, their uses as well as methods of their production are also described.

Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.

Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes.

Abstract: Pharmaceutical compositions useful for hydrophobic agents paclitaxel, paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor™ The compositions further comprise an optional tonicity agent, a buffering agent a bulking agent and a solubilizing agent which is not Cremophor™ Methods of preparing said compositions and of said compositions in the treatment of cancer are also included.

Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes.

Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic. The compounds of the invention can be used to treat any disease for which the peptide therapeutic is useful.

Abstract: Pharmaceutical compositions useful for hydrophobic agents paclitaxel, paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor™ The compositions further comprise an optional tonicity agent, a buffering agent a bulking agent and a solubilizmg agent which is not Cremophor™ Methods of preparing said compositions and of said compositions in the treatment of cancer are also included.

Abstract: The present invention features a compound having the formula A-X—B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic selected from the group consisting of neurotensin, a neurotensin analog, or a neurotensin receptor agonist. The compounds of the invention can be used to treat any disease in which increased neurotensin activity is useful and can be used to induce hypothermia or analgesia.